Navigation Links
Detection of Phosphorylated and Total ERK and p38 MAPK by Bio-Plex Assay, ELISA, and Western Blotting, Rev A

Qian Gao, Kris Simonyi, and Claudia Suen, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive, Hercules, CA 94547 USA


Introduction
Western blotting is a traditional technique for detecting phosphorylated proteins within a variety of cell culture and tissue sample lysates. In recent years, new techniques that apply a sandwich antibody capture approach have become available for detecting phosphorylated proteins. These techniques include Bio-Plex phosphoprotein assays, which are multiplex bead-based assays for the detection of one or more different phosphorylated proteins within a single sample. Enzyme-linked immunosorbent assays (ELISA) are another technique that has been increasingly applied to detect phosphorylated proteins a single target at a time. In this study, commercially available Bio-Plex phosphoprotein and total target assays, and phosphoprotein and total ELISA assays, are compared with western blotting in terms of sensitivity, detection range, and level of correlation, for the detection of phospho- and total ERK and p38 MAPK.


Methods
Lysate Preparation
Lysates of HEK 293 and HeLa cells were prepared according to two techniques. The Bio-Plex cell lysis kit was used to prepare cell lysates for western blot and Bio-Plex analysis (refer to bulletin 3033). A different lysing protocol specified in the ELISA kit vendors manual was followed to prepare cell lysates for ELISA.

Assay Procedure
The procedure detailed in bulletin 3033 was followed for western blot analysis. The procedure provided in the Bio-Plex phosphoprotein detection reagent kit was followed for the Bio-Plex phosphoprotein and total target assays (summarized in the flowchart opposite). The procedure provided in the ELISA kit vendors manual was followed for the phospho- and total protein ELISAs. The same antibodies specific to each target were used in both western blot and Bio-Plex phosphoprotein and total target assays. The antibodies used in the ELISAs were those provided in the vendor kit.


Results and Discussion
Total p38 MAPK
Total p38 MAPK was detected by ELISA in HEK 293 lysates with protein concentration ranging from 20 g/well to 0.625 g/well and absorbance ranging from 2.623 to 0.317 (Figure 1A). The limit of detection appears to be around 0.625 g/well. A similar dose response was observed with the Bio-Plex assay; however, an MFI value of 897 at the lowest data point (0.625 g/well) suggests the potential to detect further-diluted samples (Figure 1B). The data also suggest high-end saturation over 10 g/well. With the western blot, the target was detected down to a protein concentration of 1.25 g/lane (Figure 1C).

Total p38 MAPK was not detected, nor was a dose response observed with ELISA of HeLa lysates, even at the highest protein concentration tested (Figure 1D). This target was, however, detected with the Bio-Plex assay in each sample, with the MFI ranging from 4,950 to 321 (Figure 1E), which correlated well with the western blot (Figure 1F).

Phospho-p38 MAPK
Phospho-p38 MAPK (Thr180/Tyr182) was detected by ELISA in UV-treated HEK 293 lysate with protein concentration ranging from 12 g/well to 0.75 g/well (Figure 2A). The ELISA displayed a high-end saturation plateau in samples with a protein concentration from 12 g/well to 3 g/well (Figure 2A), which suggests that further dilution is necessary to detect a dose response. The Bio-Plex assay showed a distinct dose response (Figure 2B) that correlated well with the western blot (Figure 2C).

Total ERK
Total ERK1/2 was detected by ELISA in HEK 293 lysates with protein concentration ranging from 10 g/well to 0.625 g/well and absorbance ranging from 0.331 to 0.160 (Figure 3A). To explore the Bio-Plex total ERK2 assay sensitivity further, lysates were further diluted to a protein concentration range of 1.250.078 g/well (Figure 3B). In comparison, a faint band was visible on the western blot at a total protein concentration of 0.625 g/lane (Figure 3C).

Both sandwich antibody methods detected total ERK in HeLa lysates with protein concentration ranging from 13 g/well to 0.41 g/well. A flattened lower-end dose response was observed with the ELISA, and an absorbance range of 0.5000.158 showed a limited ability to distinguish between different samples (Figure 3D). The Bio-Plex total ERK2 assay better distinguished signal intensities from the high end to the low end, with MFI from 11,713 to 603 (Figure 3E). The western blot band became faint at 3.25 g/well, indicating the level of sensitivity compared to the Bio-Plex assay (Figure 3F).

Phospho-ERK
Epidermal growth factor (EGF)-treated HEK 293 cell lysates were used for phospho-ERK (Thr202/Tyr204) assay comparison. Lysates were prepared using the Bio-Plex cell lysis kit or by following a protocol provided with the ELISA kit. ELISA showed a limited ability to distinguish the first two samples, with total protein concentrations of 2 g/well and 1 g/well; the reported sample absorbance reached a plateau, and the highest OD reported was only 1.755 (Figure 4A). The Bio-Plex assay demonstrated distinctly separate signals across all the samples (Figure 4B), which correlated well with the western blot bands (Figure 4C).


Conclusions
For the detection of total p38 MAPK in HEK 293 cells, both the Bio-Plex assay and ELISA correlated well with the western blot. The Bio-Plex assay showed saturation at the high end but potential to detect the target in further-diluted samples. With the HeLa lysate, the Bio-Plex assay detected the target with good sensitivity and demonstrated a broad detection range that correlated well with the western blot bands. The target was not detectable by ELISA

For the detection of phospho-p38 MAPK in HEK 293 cells, the Bio-Plex assay demonstrated a broad detection range at the high end and good correlation with the western blot. Bio-Plex and ELISA assays both showed potential for higher sensitivity toward more dilute samples

For the detection of total ERK, the Bio-Plex assay demonstrated better signal distinction and sensitivity compared to ELISA

For phospho-ERK detection, the ELISA showed saturation at the high end. The Bio-Plex assay showed better signal distinction, dose response, and correlation with western blots compared to ELISA


The Bio-Plex suspension array system includes fluorescently labeled microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation.

Information in this tech note was current as of the date of writing (2004) and not necessarily the date this version (Rev A, 2004) was published.


back to top
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Simple, Sensitive, and Rapid Detection of FLAG -Tagged Fusion Proteins
2. A New PCR-based Mycoplasma Detection Method
3. HSVision Molecular Beacon Detection Module Rapidly Detects Herpes Simplex Virus DNA
4. Detection and Identification of Phosphorylation Sites in Proteins Using LC/MS/MS with Neutral Fragment Loss Mapping
5. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
6. Gene Expression Arrays: Highly Sensitive Detection of Expression Patterns with Improved Tools for Target Amplification
7. The DIG System Nonradioactive and Highly Sensitive Detection of Nucleic Acids
8. Quantitative Measurement of Cell Proliferation Using the BrdU ELISA: A Comparison Between Colorimetric and Chemiluminescent Detection
9. Quantification of Nucleosomes in Serum by the Cell Death Detection ELISAplus
10. A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
11. In Situ Cell Death Detection Kit
Post Your Comments:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... 11 Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company ... to treat inflammatory disease, announced today that Robert Baltera, Chief ... Annual J.P. Morgan Healthcare Conference. The presentation is scheduled ... Westin St. Francis in San Francisco, Calif. The J.P. ...
... , , , , , ... Expansion of Cooperation With Diabetes Leader Novo Nordisk, ... , The Gerresheimer Group has set up ... is to commence operations early in,2010. On the basis of a ...
... ... of advanced flow measurement, control and level solutions, has launched the redesign of ... about Brooks Instrument’s products, as well as access to Brooks experts who can ... ...
Cached Biology Technology:Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil 2Brooks Instrument Unveils New Web site 2
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... a new blood protein associated with prostate cancer, researchers ... prostate cancer antigen, can successfully detect prostate cancer in ... successfully avoids the problem of false positive results that ... in the May 15, 2005, issue of Cancer Research. ...
... similar to a drug used in the treatment of Parkinson's ... be used to develop drug therapy for cocaine abuse, new ... 23, 2005, issue of The Journal of Neuroscience, Jonathan Katz ... (NIDA) report the results of experiments showing that mice treated ...
... genetically modified to brandish a powerful "on-switch" that prompts ... finding, from researchers at St. Jude Children's Research Hospital, ... who receive treatment for acute lymphoblastic leukemia (ALL) or ... study are published in the current online issue of ...
Cached Biology News:Test for early detection of prostate cancer shows promise 2Potential Drug Target For Treating Cocaine Abuse Found 2Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells 2
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
See product name for description....
... Cryo/CryoPlus Inventory Racks for cryogenic ... with cardboard or stainless steel ... 5ml cryo vials. Vapor ... available. Platform risers to ...
Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
Biology Products: